Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 6,616

Document Document Title
WO/2009/076268A1
A method of forming a 3-phenylimino-3H-phenothiazine or a 3-phenylimino-3H-phenoxazine mediator includes providing a first reactant including phenothiazine or phenoxazine, providing a first solvent, providing a second reactant and provid...  
WO/2009/075835A1
This invention relates to novel compounds of the Formula (I), (Ia) and (Ib), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, j which are useful for the therapeutic treatment of diseases associated with...  
WO/2009/076140A1
The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.  
WO/2008/129004A3
Herein are described heterocyclic compounds containing the morpholine nucleus prepared from amino acids, their preparation and use for therapeutic applications.  
WO/2009/071658A1
The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds, to processes for their preparation, and to the use of these compounds as leptin receptor modulator mimetics in the ...  
WO/2009/071252A1
The present invention relates to nonsteroidal progesterone receptor modulators of the general formula (I), to the use of the progesterone receptor modulators for the preparation of pharmaceuticals, and to pharmaceutical compositions comp...  
WO/2009/069610A1
[PROBLEMS] To provide a compound useful as an NMDA receptor antagonist. [MEANS FOR SOLVING PROBLEMS] A study was made on a compound having an antagonistic activity on an NMDA receptor, and it was confirmed that a fused indane compound ac...  
WO/2009/070579A2
A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compo...  
WO/2009/069736A1
Disclosed is a nitrogenated compound represented by the formula (I) [wherein A represents an aryl which may have a substituent or the like; B's independently represent a hydrogen atom, a halogen or the like; n represents an integer of no...  
WO/2009/062371A1
Carbamate derivatives of 5- or 6-membered ring represented by the general formula (I), a process for preparing them, pharmaceutical compositions comprising them, intermediates for preparing the general formula (I), and a process for prep...  
WO/2009/059893A1
The present invention relates to a crystalline, enantiomerically pure hydrate of R-6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyI)-1,1-dimethy l-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one-hydrochloride of formula (1) and its activity a...  
WO/2009/058237A1
Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particular...  
WO/2008/010897A3
Disclosed is a method for preparing a compound of Formula 1 by contacting compound of Formula 2 with R1-NH2 in the presence of a carboxylic acid and a method for preparing a compound of Formula 2 by contacting a compound of Formula 4 wit...  
WO/2009/023126A3
This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for b...  
WO/2009/053277A1
The invention provides compounds of the formula (I) wherein A is selected from the partial structures A1, A2 and A3; Ry and Ry' are both hydrogen, or Ry and Ry' together with the nitrogen atom to which they are attached form a cyclic ami...  
WO/2006/102070A3
The loss of the SOST gene product sclerosti? leads to sclerosteosis characterized byihigh bone mass (HBM). In this report, we found that sclerostin could antagonize canonical, Wnt signaling in human embryonic kidney A293 cells and mouse ...  
WO/2009/048874A1
The reaction of alcohols with oxocarboxylates to form acetals or ketals is catalyzed by unexpectedly low levels of protic acids. By employing low acid catalyst levels compared to amounts conventionally used, rapid formation of acetal or ...  
WO/2007/005935A3
The present invention provides compounds and radiotracers thereof for locating, diagnosing, identifying, evaluating, detecting or quantitating NET by in vivo imaging. The invention also provides methods for locating, diagnosing, identify...  
WO/2009/044788A1
[PROBLEMS] To provide a compound useful as an agent for the treatment of circulatory diseases, nervous system diseases, metabolic diseases, reproductive system diseases, and digestive tract diseases. [MEANS FOR SOLVING PROBLEMS] The comp...  
WO/2009/043117A1
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...  
WO/2009/044707A1
Disclosed is a nitrotriazole derivative represented by the general formula (I) below. This nitrotriazole derivative is a compound useful as a synthesis reagent for synthesizing a carbamate, a carbonate and a thiocarbonate, which are usef...  
WO/2009/041095A1
This invention provides a hair dying dye formed of a compound represented by general formula (I): wherein R1 and R2 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; and An- repr...  
WO/2009/006243A3
The invention relates to processes for the preparation of the bicyclic oxazine carboxaldehyde Compound 1: (I) The invention also relates to the use of Compound 1 in the preparation of β-lactamase inhibitors.  
WO/2009/041715A1
A method of producing a compound represented by Formula (I), which comprises a step A of reacting an anthranilic acid compound with a carboxylic halide in the absence of a base, but does not comprise a step of isolating of an amide inter...  
WO/2009/041514A1
Disclosed is a hair dye composed of a compound represented by the following general formula (I). (I) (In the formula, R1 and R2 independently represent a hydrogen atom or a linear or branched alkyl group having 1-5 carbon atoms; and An- ...  
WO/2009/038548A1
The present invention provides a dually labeled oligonucleotide probe, methods of preparing and using the same. The subject probes are particularly useful for high-sensitive nucleic acid detection via hybridization assays including but n...  
WO/2009/038064A1
Disclosed is a compound useful as a type-I 11β-hydroxysteroid dehydrogenase inhibitor. Specifically disclosed is a compound represented by the formula shown below, a pharmaceutically acceptable salt thereof, or a solvate of the compound...  
WO/2009/033360A1
The present invention discloses novel benzamide derivatives represented by general formula (I), their preparation, pharmaceutical compositions containing the derivatives and their use as medicament, especially as a 5-HT4 stimulator, wher...  
WO/2009/001203A3
The present invention relates to an improved process for the preparation of Aprepitant of formula (I) and its intermediates. More particularly the present invention relates to the preparation of 3-(-S)-(4-fluorophenyl)-4-benzyl-2-morphol...  
WO/2009/022687A1
Disclosed is a compound represented by the following general formula (I). (I) (In the formula, R1 represents a hydrogen atom or the like; R2 and R3 independently represent a hydrogen atom, an optionally oxidized C1-C4 alkyl group or an o...  
WO/2008/106128A3
This invention relates to novel compounds of the Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation o...  
WO/2009/017671A1
Disclosed are syntheses of 11 β-HSDl inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance...  
WO/2009/017664A1
This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for...  
WO/2009/017190A1
Disclosed is a novel fused bicyclic compound [I] shown below, which has affinity for a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agent or the like. Specifically disclosed is a compound represented by the formul...  
WO/2009/010606A1
Models for development of new phytosanitary products based on the 1,4-benzoxazin-3-one skeleton, involved in different ecological interactions for chemical defence in plants, which have as their basic characteristic the presence of funct...  
WO/2008/052737A3
HIV protease inhibitor analogs and non-nucleoside reverse transcriptase inhibitor analogs are provided that are immunochemically equivalent to the parent compound. These analog compounds are useful as calibrators and positive controls in...  
WO/2009/011567A1
The present invention provides a novel solid form of Efavirenz, crystalline form of Efavirenz with sodium deoxycholate, designated Efavirenz : sodium deoxycholate,, methods for the preparation of Efavirenz : sodium deoxycholate, and the ...  
WO/2008/125342A3
The present invention relates to novel vanilloid receptor ligands, a method for the production thereof, pharmaceuticals containing said compounds, and the use of said compounds for the production of pharmaceuticals.  
WO/2009/005076A1
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic nephropathy. [MEANS FOR SOLVING PROBLEMS] As a result of an intensive and extensive study on compounds having antagonistic activities on...  
WO/2008/119457A3
The invention relates to novel lactam-substituted dicarboxylic acid derivatives, to methods for producing the same, and to their use in the treatment and/or prophylaxis of diseases. The invention also relates to the use of said substance...  
WO/2009/006243A2
The invention relates to processes for the preparation of the bicyclic oxazine carboxaldehyde Compound 1: (I) The invention also relates to the use of Compound 1 in the preparation of β-lactamase inhibitors.  
WO/2009/004430A1
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...  
WO/2009/001817A1
Disclosed is a compound having an excellent 11β-HSD1 inhibitory activity. Specifically disclosed is a compound represented by the following formula (I). (I) (In the formula (I), X1 represents an oxygen atom, a group expressed as -(CR11R...  
WO/2009/001203A2
The present invention relates to an improved process for the preparation of Aprepitant of formula (I) and its intermediates. More particularly the present invention relates to the preparation of 3-(-S)-(4-fluorophenyl)-4-benzyl-2-morphol...  
WO/2007/117653A3
A combination therapy treatment for cancer is disclosed using an inhibitor of the PI3K/Akt pathway and roscovitine. It is shown that combinations of roscovitine with API-2 or LY294002 induce apoptosis of androgen-dependeπt (LNCaP) and a...  
WO/2008/156443A1
A composition of matter in liquid form at a temperature of 50°C or less comprising a monofunctional benzoxazine compound embraced by the structure where R is a member selected from C1-40 alkyl, C2-40 alkenyl, each of which being optiona...  
WO/2008/076754A3
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).  
WO/2008/130616A3
The present invention provides compounds having the general structure of Formula (I) or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, which are useful as CB1 receptor antagonists. The compounds of the invention m...  
WO/2008/079339A3
The present invention pertains, at least in part, to a substituted tetracycline compound of Formula (I): wherein X is CHC(R13VY), CR6 R6, C=CR6 R6, S, NR6, or O; E is NR7dR7β, OR7f or (CH2)o.iC(=W)WR7s; W is O, S, NR711 or CR75R7*; W is...  
WO/2008/153182A1
Disclosed is a morpholine derivative represented by the formula [I] below, which is useful as a renin inhibitor, or a pharmacologically acceptable salt thereof. (In the formula, R1 represents (A) an alkyl group substituted with a group s...  

Matches 651 - 700 out of 6,616